• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,142
109
76
71
69

COUNTRY

70
22
16
10
9

CATEGORIES

  • 575
  • 121
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

1,042
1,237
1,976
3,000

PUBLISHED

26
211
660
3,000

PRODUCT TYPE

2,427
494
69
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Problem Solving in Acute Oncology

In the United Kingdom there has been increasing attention paid to the needs of cancer patients who present acutely with issues relating to their diagnosis and management, complications of their cancer,...

November 2013

US Lung Cancer Drug Pipeline Analysis

The most common type of cancer in terms of incidence and mortality rate is Lung cancer Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which...

November 2013
FROM

Global Cancer Monoclonal Antibodies Pipeline Analysis

In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer These monoclonal antibodies are designed to selectively target cancer cells and extract various responses,...

November 2013
FROM

Molecular Diagnostics in Cancer Testing

Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added The technologies that come under the umbrella of molecular...

November 2013
FROM

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein Four are aimed at improving...

October 2013
FROM

Cancer Care: Assuring Quality to Improve Survival

More than five million new cases of cancer are diagnosed every year in OECD countries Mortality rates are declining, but not as fast as for other big killers such as heart disease, and cancer survival...

October 2013
FROM

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2013

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2013', provides an overview of the indication’s...

October 2013
FROM

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013', provides an overview of the indication’s...

October 2013
FROM

Breast Cancer - Pipeline Review, H2 2013

Breast Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Breast Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Sarcomas - Pipeline Review, H2 2013

Sarcomas - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Sarcomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

October 2013
FROM

Kidney Cancer - Pipeline Review, H2 2013

Kidney Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013', provides an overview of...

October 2013
FROM

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Squamous Cell Carcinoma - Pipeline Review, H2 2013

Squamous Cell Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Squamous Cell Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Lung Cancer - Pipeline Review, H2 2013

Lung Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Indolent Lymphoma - Pipeline Review, H2 2013

Indolent Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Indolent Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Hairy Cell Leukemia - Pipeline Review, H2 2013

Hairy Cell Leukemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hairy Cell Leukemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

October 2013
FROM

Metastatic Lung Cancer - Pipeline Review, H2 2013

Metastatic Lung Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013',...

October 2013
FROM

Glioma - Pipeline Review, H2 2013

Glioma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Glioma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

October 2013
FROM
Loading Indicator

Our Clients

Our clients' logos